Yin Jin

Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (Chemo)/trastuzumab (Tra) for first-line (1L) HER2-expressing locally advanced or metastatic (la/m) gastric cancer (GC): Updated results from the RC48-C027 trial.

Zhi Peng, C Li, Xiang Wang, Yanqiao Zhang et autres

LBA4026 Background: For patients (pts) with HER2-high (defined as IHC 3+, or IHC 2+/FISH+ based on Chinese CSCO GC guidelines) GC, current 1L therapy consisting of trastuzumab combined with pembrolizumab and chemotherapy offers limited efficacy. For pts with HER2-intermediate/low (defined as IHC …

cn (code pays fourni par la source)

When AI Feels Threatening: How AI Anxiety Shapes Metacognitive Monitoring.

Yin Jin

This research will be submitted in the master’s thesis of the first author in partial fulfilment of a MPhil in Psychology & Education at the University of Cambridge Faculty of Education. As generative artificial intelligence (GenAI) becomes increasingly embedded in higher education, …

Selective Vulnerability of Executive Control in Obstructive Sleep Apnea: A Mechanistic Pathway to Memory Impairment

Liangjiecheng Huang, Yin Jin, Yuanzhi Bie, Xia Zhou et autres

BACKGROUND: Obstructive sleep apnea (OSA) is associated with widespread higher-order cognitive consequences, including deficits in memory and executive function. However, the specific cognitive architecture and underlying mechanisms that link the disease's pathophysiology to these broad cognitive changes remain poorly understood. This study …

cn, gb (code pays fourni par la source)

Metabolomics analysis of sodium butyrate's effects on lipid metabolism in lambs' rumen-blood-muscle axis

Yue Zhang, Hongbo Qu, Min Zhang, Yueying Guo et autres

This study employed metabolomics approaches to systematically elucidate the key pathways and regulatory mechanisms by which sodium butyrate modulated fatty acid metabolism in ruminants, thereby addressing the knowledge gap regarding its roles in fatty acid metabolic pathways and inter- tissue signalling mechanisms. …

cn (code pays fourni par la source)

NOLC1 suppresses immunochemotherapy by inhibiting p53-mediated ferroptosis in gastric cancer

Shengsheng Zhao, Ji Lin, Bingzi Zhu, Yin Jin et autres

Human gastric cancer (GC) is one of the most malignant cancers, and cisplatin (Cis)-based chemotherapy remains the main clinical treatment for GC. However, Cis resistance often occurs, largely limiting its therapeutic efficacy in tumors. Therefore, a better understanding of the drug resistance …

cn (code pays fourni par la source)

Author response: NOLC1 suppresses immunochemotherapy by inhibiting p53-mediated ferroptosis in gastric cancer

Shengsheng Zhao, Ji Lin, Bingzi Zhu, Yin Jin et autres

NOLC1 inhibits p53 nuclear accumulation and transcription, subsequently suppresses cisplatin-induced ferroptosis, and promotes an immunosuppressive microenvironment, eventually suppressing immunochemotherapy in gastric cancer.

cn (code pays fourni par la source)

Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer.

Lin Shen, Zhi Yong Peng, Changzheng Li, Linzhi Lu et autres

LBA4012 Background: DV+T showed encouraging efficacy with manageable safety for pts with HER2-expressing gastric or gastroesophageal junction (G/GEJ) cancer in the second- and later-line setting in a phase 1 trial (Wang et al, eClinicalMedicine, 2024). Here, we first report the efficacy and …

cn (code pays fourni par la source)

Author response: NOLC1 Suppresses Immuno-chemotherapy by Inhibiting p53-mediated Ferroptosis in Gastric Cancer

Shengsheng Zhao, Ji Lin, Bingzi Zhu, Yin Jin et autres

Gastric cancer (GC) is one of the most malignant cancers, and cisplatin (Cis)-based chemotherapy remains the main clinical treatment for GC. However, Cis resistance often occurs, largely limiting its therapeutic efficacy in tumors. Therefore, a better understanding of the drug resistance mechanism …

NOLC1 Suppresses Immuno-chemotherapy by Inhibiting p53-mediated Ferroptosis in Gastric Cancer

Shengsheng Zhao, Ji Lin, Bingzi Zhu, Yin Jin et autres

Abstract Gastric cancer (GC) is one of the most malignant cancers, and cisplatin (Cis)-based chemotherapy remains the main clinical treatment for GC. However, Cis resistance often occurs, largely limiting its therapeutic efficacy in tumors. Therefore, a better understanding of the drug resistance …

cn (code pays fourni par la source)

Multi-Functional Self-Adhesive Porous Patches with Anisotropic Charges for Abdominal Wall Repair

Shangrui Rao, Wenzhao Li, Hongzheng Li, Jianhua Lu et autres

Biomedical patches have garnered extensive value in abdominal wall repair. Major challenge still remains in the improvement of structure, function, and their active ingredients for realizing long-lasting and effective therapeutic outcomes. Herein, we develop a self-adhesive porous patch with anisotropic charges via …

cn, hk (code pays fourni par la source)

NOLC1 Suppresses Immuno-chemotherapy by Inhibiting p53-mediated Ferroptosis in Gastric Cancer

Shengsheng Zhao, Ji Lin, Bingzi Zhu, Yin Jin et autres

Abstract Gastric cancer (GC) is one of the most malignant cancers, and cisplatin (Cis)-based chemotherapy remains the main clinical treatment for GC. However, Cis resistance often occurs, largely limiting its therapeutic efficacy in tumors. Therefore, a better understanding of the drug resistance …

cn (code pays fourni par la source)

NOLC1 suppresses immunochemotherapy by inhibiting p53-mediated ferroptosis in gastric cancer

Shengsheng Zhao, Ji Lin, Bingzi Zhu, Yin Jin et autres

Human gastric cancer (GC) is one of the most malignant cancers, and cisplatin (Cis)-based chemotherapy remains the main clinical treatment for GC. However, Cis resistance often occurs, largely limiting its therapeutic efficacy in tumors. Therefore, a better understanding of the drug resistance …

cn (code pays fourni par la source)